Skip to Main Content

Paper Details

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
Ann Oncol
31
2019
ER, HER2, HER2+, HER2+ breast cancer, HER2+ tumors, HER2-positive, HER2-positive (+) breast cancers, PATIENTS, PI3K, PIK3CA, PIK3CA mutations, PTEN, breast cancer, estrogen, estrogen receptor, estrogen receptor (ER)+ tumors, invasive tumor, lapatinib, patients, trastuzumab, tumors, wild-type (WT) PIK3CA
Author NameAffiliation
Anna C PavlickLester and Sue Smith Breast Center Dan L. Duncan Comprehensive Cancer Center.
Ingrid A MayerVanderbilt University
Matthew P GoetzMayo Clinic
Jenny Chang-ClaudeHouston Methodist Cancer Center, Houston Methodist Hospital
Antonio C WolffJohns Hopkins Sidney Kimmel Comprehensive Cancer Center
Ian E KropDana-Farber Cancer Institute
Susan G HilsenbeckLester and Sue Smith Breast Center Dan L. Duncan Comprehensive Cancer Center Departments of Medicine.
Britta WeigeltMemorial Sloan Kettering Cancer Center
Jorge S Reis-FilhoMemorial Sloan Kettering Cancer Center
Charles Kent OsborneLester and Sue Smith Breast Center Dan L. Duncan Comprehensive Cancer Center Departments of Medicine Department of Molecular and Cellular Biology, Baylor College of Medicine
Mothaffar F RimawiLester and Sue Smith Breast Center Dan L. Duncan Comprehensive Cancer Center Departments of Medicine.
  • 1 - 11

Datasets

Release 1.2